ORPHA:480556
Isolated neonatal sclerosing cholangitis
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
2
12.1th percentile
Trials
0
Interventional, condition-specific
Researchers
22
Distinct authors in sample
Gene link
DCDC2
Strong
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Isolated sclerosing cholangitis is a rare, genetic, biliary tract disease characterized by severe -onset cholangiopathy with patent bile ducts and absence of ichthyosiform skin lesions. Patients present with jaundice, acholic stools, and high serum gamma-glutamyltransferase activity. Liver histology shows portal fibrosis, ductular proliferation, hepatocellular metallothionein deposits, and intralobular bile-pigment accumulations. Some patients may also have renal disease.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018816
- OMIM:617394
- UMLS:C4479344
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedPresent
Strong — DCDC2
- LiteraturePresent
2 matched papers (2 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 100 for broader category sclerosing cholangitis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (DCDC2).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
2
2 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
2 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
2 in the last 10 years · high confidence · 12.1th percentile (publications denominator)
Phrase hits: 2 · MeSH hits: 0
Who's working on it?
22
Distinct author names in 2 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Asadullina D1 paper · 2026
Institute of Urology and Clinical Oncology, Bashkir State Medical University, Ufa, Russia.
Papers in Europe PMC - 02Carvalho E1 paper · 2022
Department of Gastroenterology and Hepatology, Hospital de Base do Distrito Federal, Hospital da Criança de Brasília, Brasília 70330-150, Brazil.
Papers in Europe PMC - 03Cerski C1 paper · 2022
Pathology Department of Universidade Federal do Rio Grande do Sul (UFRGS), Pathology Service of Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre 90035-903, Brazil.
Papers in Europe PMC - 04Docena G1 paper · 2026
Instituto de Estudios Inmunológicos y Fisiopatológicos-Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), La Plata, Argentina.
Papers in Europe PMC - 05Dos Santos J1 paper · 2022
Faculty of Health Sciences, Health Science Investigation Center of University of Beira Interior (CICS-UBI), 6200-506 Covilha, Portugal.
Papers in Europe PMC - 06Dubovets A1 paper · 2026
Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, Russia.
Papers in Europe PMC - 07Enikeeva K1 paper · 2026
Institute of Urology and Clinical Oncology, Bashkir State Medical University, Ufa, Russia.
Papers in Europe PMC - 08Gainullina D1 paper · 2026
Institute of Urology and Clinical Oncology, Bashkir State Medical University, Ufa, Russia.
Papers in Europe PMC - 09Gattinger P1 paper · 2026
Division of Immunopathology, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.
Papers in Europe PMC - 10Jacinto J1 paper · 2022
Medicine Department, University of Beira Interior (UBI), Faculty of Health Sciences, 6201-001 Covilha, Portugal.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 100 trials are registered for sclerosing cholangitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
100 interventional trials matched sclerosing cholangitis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: sclerosing cholangitis
100
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06197308·RECRUITING·Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC
Conditions: Primary Sclerosing Cholangitis·Matched via name phrase
- NCT06286709·RECRUITING·FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis
Conditions: Primary Sclerosing Cholangitis · Inflammatory Bowel Diseases·Matched via name phrase
- NCT07229911·RECRUITING·A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)
Conditions: Healthy Volunteers · Primary Sclerosing Cholangitis·Matched via name phrase
- NCT05295680·RECRUITING·Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
Conditions: Primary Sclerosing Cholangitis·Matched via name phrase
- NCT06975150·NOT YET RECRUITING·Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis
Conditions: Primary Sclerosing Cholangitis (PSC)·Matched via name phrase
- NCT02137668·RECRUITING·Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
Conditions: Primary Sclerosing Cholangitis · Biliary Atresia·Matched via name phrase
- NCT07678645·NOT YET RECRUITING·The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Conditions: Primary Biliary Cholangitis (PBC) · Primary Sclerosing Cholangitis (PSC) · Atopic Dermatitis (AD)·Matched via name phrase
- NCT05835505·RECRUITING·Detoxification of the Liver In PSC (Dolphin)
Conditions: Primary Sclerosing Cholangitis·Matched via name phrase
- NCT07607353·RECRUITING·Biodegradable Stents in Primary Sclerosing Cholangitis
Conditions: Primary Sclerosing Cholangitis (PSC)·Matched via name phrase
- NCT06865924·RECRUITING·Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing Cholangitis
Conditions: PSC·Matched via name phrase
- NCT07387549·RECRUITING·A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
Conditions: Primary Sclerosing Cholangitis·Matched via name phrase
- NCT05912387·RECRUITING·Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
Conditions: Primary Sclerosing Cholangitis · Inflammatory Bowel Diseases·Matched via name phrase
- NCT07646223·NOT YET RECRUITING·Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis
Conditions: Ulcerative Colitis (UC) · Primary Sclerosing Cholangitis (PSC) · Pediatric Inflammatory Bowel Diseases·Matched via name phrase
- NCT06699121·RECRUITING·A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
Conditions: Primary Sclerosing Cholangitis (PSC)·Matched via name phrase
- NCT07341282·NOT YET RECRUITING·Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis
Conditions: Ulcerative Colitis (UC) · Primary Sclerosing Cholangitis (PSC)·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Isolated neonatal sclerosing cholangitis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Isolated neonatal sclerosing cholangitis" OR "DCDC2"
Recall-expansion terms: DCDC2
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"sclerosing cholangitis"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T17:14:09.692Z
